The state of cancer care in Russia: liver cancer - (From 22). Age-related features of the observed and relative one-year and five-year survival of patients. (clinical and population-based study). Part 2.



Cite item

Full Text

Abstract

Survival rate calculations for liver cancer patients at the federal level in the Russian Federation are only conducted in the North-Western Federal District and a few other individual administrative territories. In the first part of our study, we presented a detailed analysis of the prevalence of liver cancer, noting that the levels of standardized incidence and mortality rates in Russia and the North-Western Federal District are virtually identical, allowing us to consider the results of our study as nationally representative. The conducted research confirmed the seriousness of the issue of liver cancer among the population. However, certain advancements in patient treatment were recorded, with a significant increase in survival rates, primarily for one-year survival. For example, in the North-Western Federal District, one-year survival increased from 13.6% in 2000 to 23.1% in 2022, representing a 69.8% increase. At the same time, five-year survival rates remained largely unchanged. Increases in survival rates were observed in most age groups. A significant deficiency in the initial patient record-keeping was identified - insufficiently accurate determination of the stage of liver cancer. One-year survival rates for male and female liver cancer patients (22.7% and 22.1%) were nearly equal, as were the survival rates for liver cancer patients residing in urban and rural areas. Therefore, further improvement in the outcomes of treatment for this complex patient group can only be achieved through the implementation of regional and federal screening and epidemiological surveillance programs among populations at high and extremely high risk of developing hepatocellular carcinoma. 

About the authors

Vakhtang M. Merabishvili

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: MVM@niioncologii.ru
ORCID iD: 0000-0002-1521-455X
SPIN-code: 5705-6327

Honored Scientist of the Russian Federation, Dr.Med.Sci., Professor, Head of the Department of Oncological Statistics,  Head of the PRR of the Northwestern Federal District of the Russian Federation

Russian Federation, Saint Petersburg

Sergey S. Bagnenko

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Saint Petersburg State Pediatric Medical University

Email: bagnenko_ss@mail.ru
ORCID iD: 0000-0002-4131-6293
SPIN-code: 4389-9374
Scopus Author ID: 779096

M.D., D.Sc. (Medicine); Associated Professor, Head of Scientific Department, Leading researcher, Professor of the Department of Radiation Diagnostics and Biomedical Imaging 

Russian Federation, Saint Petersburg

Pavel V. Balakhnin

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: balahnin_p@mail.ru
ORCID iD: 0000-0002-3042-6729
SPIN-code: 1431-4012

Ph.D., Senior Researcher of the Scientific Department of Diagnostic and Interventional Radiology, Head of the Department of X-ray Surgical Methods of Diagnostics and Treatment

Russian Federation, Санкт-Петербург

Ekaterina A. Busko

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Saint Petersburg State University

Email: Katrn@mail.ru
ORCID iD: 0000-0002-0940-6491
SPIN-code: 7323-1083

DSc Med., Assoc. Prof., Leading researcher

Russian Federation, Saint Petersburg

References

  1. Berrino F., Sant M., Verdecchia V., Capocaccia R., Hakulinen T., Estéve J., eds. Survival of cancer patients in Europe: the EUROCARE Study (IARC Scientific Publications No. 132). Lyon: International Agency for Research on Cancer, 1995.
  2. Berrino F., Capocaccia R., Coleman M.P., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. Survival of cancer patients in Europe: the EUROCARE-2 study (IARC Scientific Publications No. 151). Lyon: International Agency for Research on Cancer, 1999.
  3. Berrino F., Capocaccia R., Esteve J., Gatta G., Hakulinen T., Micheli M., Sant M., Verdecchia V., eds. EUROCARE-3: the survival of cancer patients diagnosed in Europe during 1990-94. Ann Oncol 2003; 14 (Suppl. 5): pp1-155
  4. Capocaccia R., Gavin A., Hakulinen T., Lutz J.M., Sant M. (eds.) Survival of cancer patients in Europe, 1995-2002. The EUROCARE-4 study. Eur J Cancer 2009; 45.
  5. De Angelis R., Sant M., Coleman M., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E., Bielska-Lasota M., Engholm G., Nennecke A., Siesling S., Berrino F., Capocaccia R., and the EUROCARE-5 Working Group. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol 2014; 15:23-34. http://dx.doi.org/10.1016/ S1470-2045(13)70546-1
  6. Black R.J., Sharp L, Kendrick S.W. Trends in cancer survival in Scotland 1968-90. Edinburg. 1993:261.
  7. Ederer F. A simple method for determining standard errors of survival rates, with tables. J. Chron. Dis. N 11. 1960;11(6):632-45. doi: 10.1016/0021-9681(60)90062-x.
  8. Hakulinen T. On long-term relative survival rates. J Chronic Dis. 1977;30(7):431-43. doi: 10.1016/0021-9681(77)90036-4.
  9. Parkin D.M., Hakulinen T. Cancer registration: principles and methods. Analysis of survival. IARC Sci Publ. 1991;(95):159-76
  10. Merabishvili V.M. Survival of cancer patients. Issue two. Part I / Ed. Yu.A. Shcherbuk - St.Petersburg: KOSTA, 2011. - 332p. ISBN 978-5-91258-176-2.
  11. Merabishvili V.M. Survival of cancer patients. Issue two. Part II / Ed. Yu.A. Shcherbuk - St.Petersburg: KOSTA, 2011. - 408p.
  12. Merabishvili V.M. Malignant tumors in the North-West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Express-information. Fifth Issue. Editors: Prof. A.M. Belyaev, Prof. A.M. Shcherbakov. – St.Petersburg: T8 Publishing technologies, 2020. – 236p.
  13. Aareleĭd T.P. Calculation of survival rates of patients with breast cancer in the Estonian SSR, 1968-1981 // Problems in Oncology. 1986;32(12):8-12
  14. Berezkin D.P. Izuchenie vyzhivaemosti i individual'nyi prognoz pri zlokachestvennykh opukholyakh/D.P. Berezkin / Obshchaya onkologiya / Pod red. N.P. Napalkova. –L., 1989. – S. 608-632. (In Russ.).
  15. Berezkin D.P. Methods of studying the survival of cancer patients. Methodological recommendations. L.1982:24 (In Russ.).
  16. Ivanov O.A., Sukharev A.E., Starinskii V.V., Egorov S.N. Metod obrabotki bazy dannykh onkologicheskikh bol'nykh (vyzhivaemosti). Metodicheskie rekomendatsii № 97/85. M.: – 1997. – S. 23. (In Russ.).
  17. Napalkov N.P., Berezkin D.P. Printsipy i metody izucheniya vyzhivaemosti onkologicheskikh bol'nykh. Voprosy onkologii. – 1982. – № 8. – S. 10-13. (In Russ.).
  18. Petrova G.V., Gretsova O.P., Kharchenko NV. Methods of calculating survival rates. Malignant tumors in Russia in 2003 (morbidity and mortality). Chissov VI, Starinsky VV, Petrova GV, eds. M. 2005:246–54 (In Russ.).
  19. Filatov V.N. Principles and methods of studying survival as a criterion for the effectiveness of treatment of patients with malignant tumors: [DSc dissertation]. 1991:311 (In Russ.).
  20. Merabishvili V. M. On the history of the development of cancer registries in Russia, the possibility of obtaining reliable data for assessing the effectiveness of anticancer control / V. M. Merabishvili // Questions of Oncology. – 2023. – T. 69, No. 3S. – pp. 432-433.
  21. Merabishvili V. M. Methodological approaches to analyzing the activities of the oncology service based on state reporting forms and a database created in the population cancer registry of the Northwestern Federal District of the Russian Federation. Part 2 / V. M. Merabishvili, A. M. Belyaev // Issues of oncology. – 2019. – T. 65, No. 6. – P. 807-815. (In Russ.).
  22. State of oncological care for the population of Russia in 2022. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O, eds. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution "NMRC of Radiology" of the Ministry of Health of Russia. 2022:239 (In Russ.).
  23. Balakhnin P.V., Shmelev A.S., Shachinov E.G. The role of surgical technologies in the treatment of virus-associated tumors on the example of hepatocellular carcinoma. Prakticheskaja onkologija. 2018; 19(4): 348-377. – doi: 10.31917/1903348. (in Russ.).
  24. Gautier S.V., Monakhov A.R., Tsirulnikova O.M., Zubenko S.I., Sitnikova E.V., Umrik D.V., Nosov K.A., Kurtak N.D. Outcomes of liver transplantation in hepatocellular carcinoma: A single-center experience. Annaly khirurgicheskoy gepatologii. 2020; 25(2): 67-76. – doi: 10.16931/1995-5464.2020267-76. (in Russ.).
  25. Shabunin A.V., Bedin V.V., Grekov D.N., Tavobilov M.M., Drozdov P.A., Lebedev S.S., Karpov A.A., Chechenin G.M., Tsurkan V.A. Hepatocellular cancer. Current trends and the results in surgical treatment. Annaly khirurgicheskoy gepatologii. 2022; 27(3): 22-32. (in Russ.).
  26. Kotiv B.N., Dzidzava I.I., Alent’yev S.A., Smorodsky A.V., Makhmudov K.I., Apollonov A.A., Soldatov S.A., Zubarev P.N. Complex treatment of hepatocellular carcinoma at early (BCLC-A) and intermediate (BCLC-B) stages. Annaly khirurgicheskoy gepatologii. 2020; 25(2): 55-66. (in Russ.).
  27. Breder V.V., Djanyan I.A., Pitkevich M.U., Laktionov K.K., Virshke E.R., Kostyakova L.A., Kosyrev V.Yu., Trofimov I.A., Kukushkin A.V., Dolgushin B.I. Transarterial chemoembolization (TACE) efficacy in patients with hepatocellular carcinoma (HCC): Can significant prognostic factors be revealed? Voprosy onkologii. 2018; 64(6): 793-798. (in Russ.).
  28. Dzhanyan I.A. Atezolizumab and bevacizumab in the treatment of advanced hepatocellular cancer with unfavorable factors and tumor thrombosis / I. A. Janyan, M. N. Khagazheeva, V. V. Breder [et al.] // Medical Council. – 2023. – T. 17, No. 11. – P. 10-17. – doi: 10.21518/ms2023-177. (in Russ.).
  29. Petkau V.V., Bessonova E.N., Breder V.V., Tarkhanov A.A., Kiseleva K.E. Impact of a multidisciplinary approach and patient routing on the outcomes of treatment of patients with hepatocellular cancer. Malignant Tumours. 2023; 13(2): 5-11. (in Russ.).
  30. Busko E.A., Kozubova K.V., Bagnenko S.S., Karachun A.M., Burovik I.A., Goncharova A.B., Kostromina E.V., Kadyrleev R.A., Kurganskaya I.H., Shevkunov L.N. Comparative analysis of the effectiveness of CT and contrast-enhanced ultrasound in the diagnosis of colorectal cancer metastases in the liver. Annaly khirurgicheskoy gepatologii. 2022; 27(1): 22-32. (in Russ.).
  31. American College of Radiology Committee on LI-RADS® (Liver). LI-RADS Ultrasound Surveillance v2024 Core. Available at https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-US-Surveillance-v2024-Core.pdf. Accessed on January 1, 2024.
  32. Kozubova K.V., Busko E.A., Bagnenko S.S., Kadyrleev R.A., Kostromina E.V., Goncharova A.B., Burovick I.A., Okonechnikova D.V., Lyubimskaya E.S., Postanogov R.A. Comparative analysis of contrast-enhanced ultrasound and computed tomography in the differential diagnosis of focal liver lesions in patients with a history of advanced cancer. Voprosy Onkologii. 2023;69(5):897-907. (in Russ.).
  33. Zhou Y, Qin Z, Ding J, Zhao L, Chen Y, Wang F, Jing X. Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis. Front Oncol. 2022;29(12):873913. doi: 10.3389/fonc.2022.873913

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 76969 от 11.10.2019. 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies